IDDA-Scored Abatacept-to-HSCT Course in Pediatric LRBA Deficiency

LRBA deficiency is a rare inborn error of immunity in which impaired CTLA-4 recycling causes immune dysregulation; haematopoietic stem cell transplantation (HSCT) is curative, but no standardised measure of pre-transplant disease activity exists and the role of abatacept as a bridge to HSCT remains ill-defined. We report a 4-year-old girl with compound heterozygous LRBA variants in whom abatacept, given as a planned bridge to transplantation, reduced disease activity within four months (Immune Deficiency and Dysregulation Activity [IDDA] score 54.5 to 22.6), maintained control until transplant, and was followed by an IDDA of 1.0 at 22 months after HLA-matched unrelated-donor HSCT. Retrospective IDDA scoring was feasible in 32 of 46 published LRBA HSCT patients (22 with and 10 without pre-HSCT abatacept; baseline scores 11.1 vs. 11.5): overall survival was numerically higher in abatacept-exposed patients (95.8% [23/24] vs. 86.4% [19/22]); the difference was not statistically significant (Fisher exact P = 0.34), and the comparison is descriptive, underpowered, and hypothesis-generating only. The IDDA provides a practical metric to quantify disease activity and to evaluate the contribution of pre-HSCT abatacept in LRBA deficiency.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Immunology
Published
2026-11-14
DOI
https://doi.org/10.1007/s10875-026-02092-0
Primary Topic
Immunodeficiency and Autoimmune Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

IDDA-Scored Abatacept-to-HSCT Course in Pediatric LRBA Deficiency

滕丽萍, Zhaoling Wang, Bin Hu, Meiping Lu et al.
1 links
Journal of Clinical Immunology
Immunodeficiency and Autoimmune Disorders
article

IDDA-Scored Abatacept-to-HSCT Course in Pediatric LRBA Deficiency

滕丽萍, Zhaoling Wang, Bin Hu, Meiping Lu, Yan Zhang
article en

Abstract

LRBA deficiency is a rare inborn error of immunity in which impaired CTLA-4 recycling causes immune dysregulation; haematopoietic stem cell transplantation (HSCT) is curative, but no standardised measure of pre-transplant disease activity exists and the role of abatacept as a bridge to HSCT remains ill-defined. We report a 4-year-old girl with compound heterozygous LRBA variants in whom abatacept, given as a planned bridge to transplantation, reduced disease activity within four months (Immune Deficiency and Dysregulation Activity [IDDA] score 54.5 to 22.6), maintained control until transplant, and was followed by an IDDA of 1.0 at 22 months after HLA-matched unrelated-donor HSCT. Retrospective IDDA scoring was feasible in 32 of 46 published LRBA HSCT patients (22 with and 10 without pre-HSCT abatacept; baseline scores 11.1 vs. 11.5): overall survival was numerically higher in abatacept-exposed patients (95.8% [23/24] vs. 86.4% [19/22]); the difference was not statistically significant (Fisher exact P = 0.34), and the comparison is descriptive, underpowered, and hypothesis-generating only. The IDDA provides a practical metric to quantify disease activity and to evaluate the contribution of pre-HSCT abatacept in LRBA deficiency.

Journal of Clinical Immunology
Children's Hospital of Zhejiang University (CN), Zhejiang University (CN)
Good health and well-being
Immunodeficiency and Autoimmune Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon